Research map: The safety of low lipoprotein(a): a story not yet fully told

Back to the article

Papers in this map

  1. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients · The HPS2-THRIVE Collaborative Group · 2014 · 1695 citations · Cited by this paper
  2. Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome · 2026 · Related
  3. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement · Florian Kronenberg · 2022 · 1455 citations · Cited by this paper
  4. Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study · 2026 · Related
  5. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease · The HPS3/TIMI55–REVEAL Collaborative Group · 2017 · 1072 citations · Cited by this paper
  6. Rethinking antiplatelet evidence through the lens of ethnicity · 2026 · Related
  7. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial · Marc Steven Sabatine · 2017 · 605 citations · Cited by this paper
  8. Right aortic arch and double arch: current clinical challenges · 2026 · Related
  9. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial · Kausik K Ray · 2019 · 332 citations · Cited by this paper
  10. Weekly Journal Scan: Discontinuation due to adverse events varies across antihypertensive regimens · 2026 · Related
  11. Lipoprotein(a) and Risk of Type 2 Diabetes · Samia Mora · 2010 · 245 citations · Cited by this paper
  12. Epidemiological studies impacting clinical practice · 2026 · Related
  13. Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes · Daniel Fannar Gudbjartsson · 2019 · 230 citations · Cited by this paper
  14. AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension · 2026 · Related
  15. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population · Lin Ding · 2015 · 118 citations · Cited by this paper
  16. Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction · 2026 · Related
  17. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment · Gregory G. Schwartz · 2021 · 40 citations · Cited by this paper
  18. Spotlight on EHRA 2026: illuminating arrhythmia management · 2026 · Related
  19. Therapeutic Potential of Lipoprotein(a) Inhibitors · Stephen James Nicholls · 2024 · 33 citations · Cited by this paper
  20. Improving individual lifetime cardiovascular disease risk estimation to optimize secondary prevention · 2026 · Related
  21. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials · Lawrence A. Leiter · 2024 · 25 citations · Cited by this paper
  22. Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial · Gregory G. Schwartz · 2025 · 11 citations · Cited by this paper
  23. Inverse Association of Lipoprotein(a) on Long-Term Bleeding Risk in Patients with Coronary Heart Disease: Insight from a Multicenter Cohort in Asia · Peizhi Wang · 2023 · 7 citations · Cited by this paper
  24. Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes? · Pablo Corral · 2025 · 6 citations · Cited by this paper
  25. Safety of low lipoprotein(a) levels: the FOURIER trial · Bariş Gencer · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)